This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Enhabit (EHAB) Panoramica del titolo
Enhabit, Inc. fornisce servizi di assistenza sanitaria domiciliare e di hospice negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Enhabit, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$13.80 |
| Massimo di 52 settimane | US$14.22 |
| Minimo di 52 settimane | US$6.47 |
| Beta | 0.96 |
| Variazione di 1 mese | 0.51% |
| Variazione a 3 mesi | 23.66% |
| Variazione di 1 anno | 29.70% |
| Variazione a 3 anni | 16.06% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -44.80% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Aggiornamento della narrazione • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Aggiornamento della narrazione • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Recent updates
Aggiornamento della narrazione • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Aggiornamento della narrazione • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Aggiornamento della narrazione • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Aggiornamento della narrazione • Mar 10
EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Seeking Alpha • Feb 25
Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Summary Enhabit Inc. is being acquired by Kinderhook Industries for $13.80 per share, an all-cash deal at an enterprise valuation of $1.1 billion. I see minimal antitrust risk, as Kinderhook lacks significant overlap in hospice care, making regulatory intervention unlikely. EHAB trades at a discount to peers due to higher debt and inconsistent profitability, but the acquisition premium reflects limited market optimism. With only a 1.8% spread to the deal price and limited upside, I rate EHAB a Hold pending deal completion. Read the full article on Seeking AlphaAggiornamento della narrazione • Feb 24
EHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.Aggiornamento della narrazione • Feb 08
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.Aggiornamento della narrazione • Jan 25
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.Aggiornamento della narrazione • Jan 10
EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.Aggiornamento della narrazione • Aug 08
Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.Articolo di analisi • Jul 03
Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Enhabit, Inc. ( NYSE:EHAB ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Jun 14
Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Nuova narrazione • May 29
US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.Articolo di analisi • May 09
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Articolo di analisi • Apr 09
Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Seeking Alpha • Feb 03
Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Summary EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. Valuation models suggest higher upside potential, with best case scenario implying a target price of $11-$12 per share. Read the full article on Seeking AlphaArticolo di analisi • Dec 14
Is Enhabit (NYSE:EHAB) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Nov 07
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Articolo di analisi • Jul 17
Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jul 15
Is Enhabit Dead? Not Quite Yet
Summary It is soon to be the last independent home health and hospice company. Scarcity value could drive interest from financial and strategic bidders. Shareholders have a slate of new directors to refresh the company. Read the full article on Seeking AlphaArticolo di analisi • Jun 19
Enhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Articolo di analisi • May 10
An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enhabit fair value estimate is US$14.19 Enhabit is estimated...Articolo di analisi • Mar 09
Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
It's been a pretty great week for Enhabit, Inc. ( NYSE:EHAB ) shareholders, with its shares surging 17% to US$10.34 in...Articolo di analisi • Mar 05
The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 0.4x Enhabit, Inc. ( NYSE:EHAB ) is a stock worth checking...Articolo di analisi • Feb 09
Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Rendimenti per gli azionisti
| EHAB | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | 0.07% | 2.9% | 0.9% |
| 1Y | 29.7% | 18.7% | 24.5% |
Ritorno vs Industria: EHAB ha superato il US Healthcare che ha restituito 18.7 % nell'ultimo anno.
Rendimento vs Mercato: EHAB ha superato il mercato US che ha restituito 24.5 % nell'ultimo anno.
Volatilità dei prezzi
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: EHAB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di EHAB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. fornisce servizi di assistenza sanitaria a domicilio e di hospice negli Stati Uniti. Il segmento Home Health offre assistenza infermieristica, terapia fisica, occupazionale e logopedia, assistenza medica e sociale e servizi di assistenza sanitaria a domicilio. Questo segmento fornisce anche servizi di educazione del paziente, gestione del dolore, cura delle ferite e cambio delle medicazioni, riabilitazione cardiaca, terapia infusionale, somministrazione di farmaci e servizi di osservazione e valutazione qualificata; pratiche per il trattamento di malattie e condizioni croniche, tra cui il diabete, l'ipertensione, l'artrite, il morbo di Alzheimer, l'ipovisione, la stenosi spinale, il morbo di Parkinson, l'osteoporosi, la cura di ferite complesse e il dolore cronico, oltre a piani specifici per i pazienti affetti da diabete, insufficienza cardiaca congestizia, post-operazione o infortunio ortopedico e malattie respiratorie; consulenza per i pazienti e le loro famiglie in merito alle preoccupazioni finanziarie, personali e sociali che derivano dai problemi di salute del paziente.
Enhabit, Inc. Riepilogo dei fondamenti
| EHAB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$706.91m |
| Utili (TTM) | -US$3.20m |
| Ricavi(TTM) | US$1.06b |
0.7x
Rapporto P/S-220.9x
Rapporto P/EEHAB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EHAB Conto economico (TTM) | |
|---|---|
| Ricavi | US$1.06b |
| Costo del fatturato | US$544.20m |
| Profitto lordo | US$520.70m |
| Altre spese | US$523.90m |
| Utili | -US$3.20m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.062 |
| Margine lordo | 48.90% |
| Margine di profitto netto | -0.30% |
| Rapporto debito/patrimonio netto | 72.7% |
Come si è comportato EHAB nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/16 13:18 |
| Prezzo dell'azione a fine giornata | 2026/05/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Enhabit, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |